View more job listings or post a job
Gilead Sciences Senior Research Associate, Drug Metabolism
Gilead Sciences Research Scientist, Drug Metabolism
Gilead Sciences Principal Scientist, Drug Metabolism
Gilead Sciences Research Scientist, Drug Metabolism
Theravance Biopharma Associate Scientist
Gilead Sciences Associate Scientist (Contractor)
Evotec/Genentech Contractor Scientific Researcher/Sr. Scientific Researcher in Protein Chemistry
Evotec/Genentech Contractor Scientific Researcher/Sr. Scientific Researcher in Protein Chemistry
Applied Photophysics Application Scientist
Genentech Associate Scientist(Contract)
Post a job

Seminar luncheon

Convertible CAR-T cells with a steering wheel, accelerator, and brake for cancer therapy

Speakers: David W. Martin, MD, Chairman and Chief Scientific Officer, Xyphos Bioscience
Organizers: Shichang Miao, PhD
Date: 12/14/2018
Time: 11:00-14:00
Registration fee (USD): ;
Location: SF Bay Area: Foster City Crowne Plaza
Major Sponsor:
Vendor show vendors registered to date: (4)BioTechne (R&D Systems); DyChrom; Novogene Corporation; PHC former Panasonic Healthcare
Registration deadline:12/11/2018  (it will close sooner if the seating cap is reached)

About the Topic

The recent progress in the field of immuno-oncology has dramatically changed the clinical approach to treating cancer. Tremendous excitement centers on Adoptive Cell Therapy (ACT), an approach that delivers living cells derived from the human immune system and engineered to target and kill cancer cells. Results from numerous clinical studies of pioneer CAR-T therapy products showed tremendous success and provided evidence of complete and durable cancer remissions. However, at the same time, many challenges to effect safe and effective CAR-T therapy became evident.

Building on the success of the pioneer CAR-T therapies, Xyphos is developing best-in-class CAR-T therapy products based on our ACCEL technology which includes our universal 
CAR and a family of bispecific, antibody-like adaptor molecules, called MicAbodies™ and MicAdaptors. Our vision is to provide precision, control, safety and ultimately durable efficacy to this revolutionary class of cancer therapy. Further details are at

About the Speakers

DAVID W. MARTIN, MD, Chairman and Chief Scientific Officer

Dr. Martin is a Co-founder of Xyphos. He has previously held executive and scientific leadership roles in biotechnology and pharmaceutical companies including SVP of R&D at Genentech (1982-1990); Executive VP of R&D at DuPont Merck (1991-1993); President of Chiron Therapeutics (1994-1995); and Founder and CEO of Eos Biotechnology (1997-2003); and Co-founder and CEO of AvidBiotics (2004-2017). Additionally, he has served as Director and Lead Director of Cubist Pharmaceuticals and Varian Medical Systems, each for more than a decade. Dr. Martin trained at Duke Medical School, was Professor of Medicine and Biochemistry at University of California, San Francisco, and Investigator of the Howard Hughes Medical Institute. He is currently a member of the Oversight Committee for the California Institute for Regenerative Medicine.

2019-03-07, Promising Therapeutic Approaches and Translational Medicine to Advance Novel Therapeutics (A Joint Symposium by PBSS and Stanford SPARK Program)
2019-03-11, Clinical Trials Essentials: An Intensive One-Week Course (register for the full week or half day sessions)
2019-04-25, Tox 21 and New Approach Methodology (NAMs): Using Emerging Technologies to Improve Translational Research and Safety Assessment Predictions (jointly by SOT-NorCal & PBSS)
2019-05-06, CMC Development for Biologics: Purification, Formulation, Analytical Characterization, Production Systems, Regulatory and Product Development
2019-06-11, Advances in Immuno-Oncology (A Joint Symposium by PBSS and BioScience Forum)
2019-09-13, Biotransformation and Disposition of Larger Molecules: Peptides, Nucleotides, Proteins, mAbs, and ADCs
2019-10-03, Bioanalytical Method Validation & Regulated Bioanalysis: Fundamentals, the New FDA Guidance and Regulatory Trends
┬ęPharmaceutical & BioScience Society, International; Last Modified: 2/23/2019; Visited: 466; Admin Logon
Ads (in random order)
Submit a Text Ad
($200 for 2 months)

MicroConstants MicroConstants is a GLP-compliant Contract Research Organization focused on performing regulated bioanalysis, drug metabolism and PK analysis.
Submit a Text Ad